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Abstract
Purpose of Review Long-term culture of adult progenitor
cells in 3D is a recently emerging technology that inhabits
the space between 2D cell lines and organ slice culture.
Recent Findings Adaptations to defined media components
in the wake of advances in ES and iPS cell culture has led
to the identification of conditions that maintained intestinal
cell progenitors in culture. These conditions retain cellular
heterogeneity of the normal or tumour tissue, and the
cultures have been shown to be genetically stable, such that
substantial biobanks are being created from patient derived
material. This coupled with advances in analytical tools has
generated a field, characterized by the term ‘‘organoid
culture’’, that has huge potential for advancing drug dis-
covery, regenerative medicine, and furthering the under-
standing of fundamental intestinal biology.
Summary In this review, we describe the approaches
available for the long-term culture of intestinal cells from
normal and diseased tissue, the current challenges, and how
the technology is likely to develop further.
Keywords Intestinal  Organoid culture  Intestinal cell
progenitors  Cancer stem cell  Disease models 
Colorectal cancer
Introduction
In 2007, after decades of research, the intestinal cell pro-
genitors (ICPs) that are responsible for regenerating the
surface of the normal intestine every 2–7 days were iden-
tified and shown to reside within crypt bases of the
intestinal epithelium [1]. Up to this point, a variety of
approaches had been used in an attempt to grow this tissue
in vitro, including 2D immortalized cell lines often derived
from either benign or malignant tumours, short-lived pri-
mary tissue isolates, as animal xenografts, and tissue pie-
ces/slices. Each system not only had strengths but also
shortcomings such as limited population doublings (pri-
mary isolates), ethical concerns (xenografts), or short-term
viability (tissue slices). Following the identification of the
ICPs, there was a period that saw major advances in the
understanding of basic stem cell biology and refinements of
progenitor cell culture. In 2007, it was demonstrated that
3D spheroids derived from CD133? intestinal cancer stem
cells (CSCs) could be maintained by utilizing culture
medium refinements from neurosphere culture methods [2].
This formed part of a progression of developments, mainly
pioneered by researchers then based within the laboratory
of Hans Clevers, that in 2009 led to the identification of
Lgr5 as an ICP marker and publication of a 3D culture
technique which allowed single murine intestinal stem cells
to be grown into organoids that contained protruding crypt
structures with all the cell lineages that comprise the small
intestinal crypt in vivo [3, 4, 5•]. These cultures were
grown in a mesenchyme-free environment comprised
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Matrigel (a reconstituted basement membrane gel [6]) in a
medium with three organoid supporting supplements: epi-
dermal growth factor (EGF); Noggin, which is a BMP
signalling inhibitor that maintains an undifferentiated state;
and R-Spondin, a modulator of the Wnt pathway and potent
stimulator of adult stem cell proliferation [7]. The gener-
ation of mice harbouring an Lgr5 driven GFP reporter [8]
has enabled work that further characterized the crypt niche
[9] along with identifying other ICP markers, notably Bmi1
[10], and indeed proved crucial to the identification of
R-Spondin as a key modulator of Wnt signalling. It was
later observed that cultures of mouse colonic epithelium
required the addition of Wnt3A to enable their indefinite
expansion, suggesting that the organoid Wnt ligand pro-
duction is insufficient to maintain colonic stem cells [11].
This work was then successfully translated into patient-
derived ICP containing organoids utilizing similar media,
although human intestinal and colonic organoids required
both p38 and TGF-b inhibition (to suppress differentia-
tion), with human colon culture additionally requiring
Wnt3A, Prostaglandin E2 (that promoted organoid integrity
through blocking anoikis and promoting proliferation), and
Nicotinamide (a vitamin shown to inhibit differentiation)
[11, 12].
This review discusses the progress made over the last
3 years in using organoid culture of tissue-derived ICPs.
Related developments in which intestinal cultures are
generated by the directed differentiation of embryonic or
induced pluripotent stem cells are described and reviewed
elsewhere [13–16]. Within this review, we will introduce
the areas in which long-term tissue-derived ICP cultures
are finding utility; (1) their application in studying disease
processes (particularly CSC biology), (2) the prospective
clinical applications of long-term ICP culture models, (3)
the ongoing cell culture refinements and elaborations of
ex vivo ICP models, and (4) an overview of the analytical
technologies around the use of ICP organoids that will lead
to the proliferation of ICP organoid platforms.
Study of ICPs in Disease
ICP-generated 3D organoids retain in vivo cell-to-cell
contacts, mass transport properties, mechanical properties,
and metabolic profiles, whilst incorporating many cell
types, modelling cell proliferation/differentiation, com-
bined with long-term genomic stability [17•] and gene
expression patterns. Thus, the organoids maintain their
integrity, unlike classical 2D cell culture with its inherent
loss of heterogeneity and the genomic rearrangements
associated with the culture ‘crisis’/cellular senescence
events that occur during cellular adaption. This mainte-
nance of cell identity and genetic integrity within ICP
containing organoid cultures makes them the current gold
standard tool for interrogating basic and diseased intestinal
biology ex vivo and the protocols for isolation of human
intestinal progenitor cells from resected surgical samples
and biopsies are now well established [18, 19]. Indeed the
derivation of ICP organoid cultures from normal tissue and
tumour material is carried out in such a way that cells are
never grown directly upon culture plastic, as opposed to
spheroid or tumoursphere culture models that are generated
from established 2D cell lines. These organoid cultures
have been particularly used in the study of colorectal
cancer (CRC), and are being applied to translational set-
tings such as regenerative medicine, diagnostic tests, and
disease modelling [20–24].
CRC Modelling Using Ex Vivo ICP Culture
Ex vivo ICP culture has been highly relevant in CRC,
where the ISC has been identified as the cell of origin [25].
Previously, cancer research has relied heavily on the use of
genetically modified mouse models (GEMMs) to explore
the genes and pathways associated with the disease.
However, these models predominantly develop tumours in
the small intestine and not the large intestine, the reverse of
the human situation. Indeed, for the time being ex vivo
ICP-based culture systems do not yet fully recapitulate
in vivo 3D architecture, nor the contributions of the stroma,
endothelial cells, oxygen tension, blood supply, immune
system, or innervations that are afforded by CRC GEMMs.
Further, the herbivorous mouse small intestine microbiome
bears little resemblance to the omnivorous human large
intestine microbiome and does not model the significant
role that the environment plays in CRC risk. Despite these
current drawbacks, the potential major benefit of long-term
ICP culture will be the reduction in the current reliance on
GEMMs and a shift towards using human and mouse
organoid cultures and systems that will increasingly reflect
the in vivo CRC environment. Indeed, establishing reliable
sources of this material is now crucial for researchers to
understand normal and malignant ICPs. The following
section will summarize the recent developments in using
diseased ICP cells that have either come from patients,
GEMMs, or that have been ‘engineered’/gene edited from
one of the first two sources.
Patient-Derived ICPs
There are a number of paths to modelling CRC based upon
the culture of ICPs, perhaps the most direct involving the
collection of patient tumour material and the preparation of
stable long-term cultures. This has led to the development
of CRC organoid collections (or biobanks) which have the
aim of representing the diversity of CRC disease, infection,
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and drug responses that exists within the patient population
[17•, 26, 27]. An issue with such an approach is the need to
develop a biobank that truly reflects the main disease
subtypes. There are currently four clinical subtypes of CRC
that have been recently assigned by the CRC Subtyping
Consortium, they are microsatellite instability immune
(CMS1; characterized by hyper-mutated, microsatellite
unstable and strong immune activation), canonical (CMS2;
epithelial, with marked Wnt and Myc signalling activa-
tion), metabolic (CMS3; epithelial and evident metabolic
dysregulation), and mesenchymal (CMS4; prominent TGF-
b activation, stromal invasion, and angiogenesis) [28]. The
interpretation of drug response studies is notably more
complex in the CMS1 subtype because whilst the genetic
changes will classify the cultures the impact of immune
cell components is missing from the assay readouts [17•].
Such collections require not only enough patients per
subtype to power future analysis, but also culture condi-
tions that address concerns regarding any selective bias
favouring one CRC subtype over another. The key
advantages of patient-derived ICP cultures are the capture
of genetic combinations that are known drivers of human
disease, the maintenance of disease associated epigenetic
history, and the ability to recapitulate the histology of
primary disease.
GEMM-Derived ICPs
The second major source of malignant ICP cultures is from
genetically characterized GEMMs. Despite the drawbacks
previously mentioned, they are still invaluable tools for
research and can be combined with organoid culture to
great effect. This was epitomized by the work from the
group of Doug Winton, who used ICPs from GEMMs to
generate organoids that could contain a singly mutated ICP
to understand the altered crypt dynamics and clonal
advantage induced by the most common genetic alterations
pervading CRC biology (Apc loss, Kras activation, and P53
mutation) [29]. Indeed over the past 3 years, GEMMs and
organoids have been used to investigate the myriad of ISC-
and CRC-associated genes and their relevant pathways to
identify which are driving the tumour and which are pas-
sengers, e.g. Troy [30], Brg1 [31], Cdx2 [32], Kcnq [33],
Prox1 [34], Fzd7 [35], Yap [36]. As well as the continuing
exploration of intestinal biology, the GEMM-derived
organoids are also being deployed as platforms to screen
how normal gut and primary tumours with defined muta-
tions respond to potential cancer therapeutics and deter-
mine the mechanisms of action. For example, Lorenzi
et al. have used this approach to demonstrate that the
resistance of FBXW7-mutated CRC cells to certain types of
chemotherapy (e.g. Fluorouracil (5-FU)) is due to an
inhibition of terminal differentiation indicating the that
they could be overcome by using differentiating therapies
[37]. ICP culture has been used to investigate the p300-
CREB-MYB protein interactions and its role in Oxaliplatin
resistance [38]. It has been demonstrated that the changes
in gene expression pattern in a malignant intestinal stem
cell are also closely tied to radiation resistance; Ladang
et al. identified that the expression of Elp3 plays a key role
in the radio-resistance of the Lgr5?Dclk1? malignant ISC
due to its promotion of Sox9 translation [39]. There are of
course limitations to GEMM work that are driving the
development of the human CRC models described above,
such as the costs associated with their creation, their
maintenance, and their inability to accurately reflect the
biology of the human large intestine, particularly as the
majority of GEMM studies on intestinal tumourigenesis
have performed in the mouse small intestine. A key
advantage going forwards will be the ability to reduce the
cost of GEMM studies through combining defined genetic
backgrounds with the ability to establish them as long-term
organoid cultures and in doing so obtain much more data
per animal.
Genome Editing of ICPs
A third approach capable of utilizing both of the above
CRC culture derivations is through the exploitation of
current DNA manipulation technologies to manipulate
normal mouse and human ICPs into cancer ICPs that reflect
human CRC. Using shRNA to target APC, P53, and PTEN,
Onuma et al. have used lentiviral vectors in normal ICPs
that has enabled them to generate recapitulated intestinal
tumour organoids without generating gene-modified mice
[40]. Similarly, Wang et al. [41] using adenovirus vectors
and Ju et al. using food derived exosome delivery of
nanoparticles [42] have provided proof of principle studies
to demonstrate these techniques as effective gene delivery
vehicles for genetic manipulation in 3D organoid cultures.
However, future work is likely to use genome editing
technology to a greater extent. The groups of Toshiro Sato
and Hans Clevers have pioneered the use of CRISPR-Cas9
in ICP culture to demonstrate that common CRC mutations
(often termed as ‘driver mutations’) confer niche-inde-
pendent stem cell maintenance but not to metastatic pro-
gression, with data indicating that additional molecular
lesions are also necessary for invasive tumour behaviour
[43•]. A key feature of these techniques is the ability to
modify genes in a stepwise fashion enabling the immediate
analysis of the effect each gene has on an ICP [40, 44]. ICP
culture has demonstrated that oncogenic alterations acti-
vating the MAPK and Wnt/b-catenin pathways must be
consecutively and coordinately selected to assure stem cell
maintenance during colon cancer initiation and progression
[45]. Germann et al. [46] used organoids generated from
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Apcmin/? mice noting an aberrant cyst-like sphere mor-
phology induced by a constitutively activated Wnt pathway
that was responsible for increasing both self-renewal and
growth while reducing differentiation. This observation
combined with deletion studies elegantly described the
engagement of the Wnt, Notch, and Myb transcriptional
pathways in intestinal tumourigenesis and further high-
lighted the Wnt pathway as a therapeutic target in CRC. It
seems likely that these last techniques will slowly lead us
away from our current reliance on GEMMs.
Clinical Applications of Long-Term ICP Culture
Models
This section summarizes in turn, personalized medicine,
drug discovery, and regenerative medicine, the three main
areas of clinical application for long-term ICP cultures.
Personalised Medicine
One of the greatest potential benefits of ICP cultures is to
deliver a personalized medicine paradigm, where much
like a biomedical service such as microbiology or virobi-
ology a small sample is supplied and then cultured for rapid
analysis. Where cultures act as ‘avatars’ of patients in the
dish, an emerging application recently summarized by [47]
allows clinical feedback of sample response to available
therapeutics (Fig. 1). Ideally, these samples could also seed
the biobanks described in the previous section, increasing
the potential to break the existing 2D cell line paradigm
that is prevalent in commercial drug/toxicity testing [48].
Drug Discovery
Diverse collections of patient samples reflecting population
disease profiles may power future drug discovery pro-
grammes, wherein organoids representative of specific
disease subtypes would be tested against panels of com-
pounds in drug titration assays in order to determine their
potential efficacy. Key to shifting the current 2D culture
led paradigm will be the generation of defined batches of
organoids through scalable processes for commercial drug
discovery programmes. Already the use of ICP culture is
currently expanding knowledge of the role of individual
genes in response to injury [49], and chemical-induced
injury, e.g. ID1 [50].
Regenerative Medicine
Increasing our understanding of the influence of diet on the
ISC using ex vivo culture is identifying the mechanisms for
understanding the cause of disease resistance and
simultaneously opening up potential avenues to be
exploited for regenerative medicine. Potentially, the rela-
tionship between a high fat diet (which has been shown to
increase the self-renewal potential of intestinal organoids),
and susceptibility to CRC could be exploited to aid
regeneration following intestinal injury [51]. Further, it has
recently been demonstrated that transplantation of ICP
organoids can potentially be used to increase the absorptive
area in patients with short bowel syndrome [52] or alter-
natively tissue reconstruction, i.e. bowel reconstruction
after disease, could be achieved using de-cellularized
scaffolds for growing functional epithelium. The tools of
organoid culture have also been explored in single-gene
hereditary defects affecting the intestine, notably in studies
of the cystic fibrosis transmembrane conductor receptor
where organoids derived from the ISCs of cystic fibrosis
patients have facilitated functional studies, drug develop-
ment, personalized medicine, and gene repair approaches
to treating the disease [53–55]. Gene manipulation in vivo
and ex vivo has led to the conversion of ICPs into insulin
producing ‘‘neo b-cell islets’’, providing a potentially
abundant and accessible source of functional insulin pro-
ducing cells [56].
However, for organoids to achieve their clinical poten-
tial, biobanks of intestinal disease (i.e. CRC) would ideally
(1) contain the tumour, blood (germline DNA), and early
passage organoid set for DNA/expression analysis, which
would allow the checking for a faithful recapitulation of the
tumour by the organoid culture, alongside the identification
of mutations from polymorphisms, (2) the ability to sup-
ply/maintain organoids in sufficient quantities and under
standardized conditions to facilitate drug titration assays,
which will require the development of bioreactors capable
of standardizing growth and assay material, and (3) a
sample collection reflecting a broad genetic diversity
enabling toxicity studies where the range of likely toxic
responses can be monitored.
Advances in Ex Vivo ICP Culture
Increasingly, the literature demonstrates a proliferation of
the use of, and the number of, applications of ICP models
(Table 1). Indeed, there have been some attempts to define
and standardize conditions through publications of detailed
protocols [57], and commercial production of specific
media. Further streamlining of key components of the
culture platform will be required to generate fully defined
and reproducible growth conditions, a key example is the
3D support/extracellular matrix. The most commonly used
support matrix, Matrigel, is a biological derived product
that has a protein matrix composition of laminin, entactin,
collagen, and heparan sulphate proteoglycans with batch
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variations compounded by varying concentrations of
growth factors, such as bFGF, EGF, IGF-1, PDGF, NGF,
and TGF-b [58]. Despite the work of some groups to date a
defined hydrogel suitable for long-term ICP culture has not
been reported, matrix biologists from the field of directed
stem cell differentiation are now engaging with organoid
culture [59].
Aside from standardization of existing models, ongoing
elaborations of ICP niche culture are being pursued in
efforts to draw models still closer to recapitulating the
organ in a dish (Table 1). There are a growing number of
co-culturing methods to elaborate organoids with other cell
types from the intestinal niche: (1) nerve and fibroblast
cells replacing the need for exogenous Wnt signalling [60],
myofibroblasts [61–63], gut nerve cells [64], (2) microor-
ganisms of the gut microbiome modulating nutrient avail-
ability [65, 66], and (3) the use of microfluidics to explore
niche dynamics [67, 68] (Table 1). Many of the above uses
of these cultures are also discussed by Fatehullah et al.
[69]. Again, the key is to refine culture techniques that
accurately replicate the in vivo environment whilst
addressing the challenge of establishing reproducible
Fig. 1 Schema showing the
scope of tissue-derived ICP
culture. a Intestinal cell
progenitor culture, the origin of
different organoids (normal and
disease). b A collection of
techniques and technologies that
need to be in place in order to
fully exploit the potential of ICP
long-term cultures, for example
the need for rapid genotyping to
ensure the integrity of cultures
from passage to passage. c The
main applications and areas of
ongoing research for potential
deployment long-term ICP
cultures in biomedical and
clinical settings
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systems suitable for their application in drug discovery
programmes.
Analysis of ICP Organoids
The use of ICP culture and technology to alter gene
behaviour can elicit a myriad of cellular biology; thus,
there is a requirement for techniques that can be used to
analyse and quantify relevant parameters within complex
3D cellular environments [19]. This section sets out the
cell culture analysis tools that can be used with 3D orga-
noid cultures to quantify the complexity of organoid sys-
tems that display a wider range of biology compared with
‘classical’ 2D culture models. In some cases, tools have
been modified to better work in 3D culture conditions.
3D Organoid Visualization
A change from 2D to 3D biology represents a sizable image
analysis challenge. Standard light microscopy image anal-
ysis (often achieved using whole well or plate scanning
imaging apparatus) is limited to 2D images, offering rela-
tively few extra parameters (i.e. organoid diameter, organoid
area, and number of organoids), although they do facilitate
non-destructive serial measurements. In order to exploit the
readouts of commonly used immunohistochemistry and
immunofluorescence methods (for example live/dead cell
detection, cell polarity, cell lineages, and organoid archi-
tecture), microscopic imaging platforms, such as wide field
and confocal high content microscopes, are being used to
analyse organoid cultures in 3D. Software analysis pipelines
that are capable of analysing hundreds of 3D morphometric
parameters and readouts can be used to identify subtle bio-
logical effects of media conditions and drug treatments [70].
These workflows are being designed to be compatible with
the medium- to high-throughput drug screening demands of
the pharmaceutical industry, and have led the development
of morphometric analysis tools able to handle and interpret
the volume of image stacks generated. The power and con-
tinued evolution of these screening platforms will be needed
if 3D ICP-containing tumour models are to replace 2D cell
lines in the preclinical drug discovery process. Image anal-
ysis of organoids may also be aided by the development of
label-free imaging approaches such as coherence anti-
Stokes–Raman spectroscopy (CARS) since cell type iden-
tification within complex 3D cellular environments cur-
rently requires organoid fixation and permeabilization
[71, 72]. With the enhanced microscopy platforms, such as
CARS, it will very likely be the timely analysis and inter-
pretation of massive volumes of data created that represent
the rate-limiting step to their application in drug screening
and discovery programmes.T
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Single Cell Analysis
The ability to isolate and examine single cells within an
organoid is an important feature of ICP culture. As the next-
generation single-cell gene profiling becomes increasingly
available in research labs, further progress will be made in
understanding intestinal biology and disease. Existing next-
generation sequencing technology has already been adapted
and exploited to identify new intestinal cell types within
organoids based on single cell messenger RNA sequencing
[73]. This will allow lineage tracing experiments and a
greater understanding of the dynamics of normal and dis-
eased cells within the crypts. Although the readouts are still
relatively limited, standard biochemical assays (live/dead
ATP assays) have also been adapted for use in 3D culture,
and other bioassay techniques are also coming on line.
Techniques such as those reported by Fan et al. [74] wherein
they adapted existing tools to create a platform capable of
tracking dynamic energy metabolism in organoids and
demonstrated a Warburg-like metabolic profile associated
with colon tumourigenesis.
For the current rate of progress in the use of organoids to
be maintained, it will be important that the development of
technology, for obtaining and interpreting the vast quanti-
ties of information that can be gained from long-term ICP
cultures, does not lag far behind.
Bringing Ex Vivo Closer to In Vivo: The Next
Challenge
The complexity of the intestinal niche necessitates further
elaboration of culture model systems that will likely
include gut microbiota and diet research. Current models
do not include stroma, elements of the immune system, a
disease-specific ECM, or gut bacteria (the latter applica-
ble to drug development for infection models). The ability
of ICPs to faithfully maintain physiological relevance
over time is vitally important for their use as research
tools. However, replicating the environment in the human
large intestine is crucial to our understanding how CRC
develops. Culture conditions that manipulate the sig-
nalling pathways essential for ISC function are continu-
ally being identified and refined to better replicate and
understand the ISC niche [75, 76]. Recent research has
taken a reductionist approach to begin understanding the
enormous complexity of this system. Reports investigat-
ing the role of single components of the diet [51],
microbiome [26, 77–81], metabolome [66], immune sys-
tem [81], and stroma [63, 82] on ICP using ex vivo
culture are starting to emerge. These have demonstrated
an increased understanding of how the environment elicits
cellular and epigenetic alterations [83, 84] that are
relevant to human health and intestinal diseases. Beyaz
et al., using an ex vivo model, recapitulated ex vivo the
environment associated with a high fat diet and estab-
lished a PPARd-dependent link to an increase in stemness
within the intestinal niche that predisposes to CRC.
Although these reductionist approaches are yielding
greater insight into ICP, ultimately there will need to be
greater efforts made to bring ex vivo culture techniques
closer to the in vivo environment. The challenge for the
future is to develop the tools for ICP culture to the point
where human intestine can be recapitulated in the labo-
ratory, such as elaborate co-culturing systems involving
microfluidic linked culture vessels mimicking multi-
compartment and even multi-tissue interactions. This
would enable the exploration of the interactions between
the full range of factors (diet, microbiome, metabolome,
stroma, and immune system) that impact on the ISC and
the roles they play in promoting, preventing, initiating,
and driving intestinal diseases.
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